{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-003631","form_type":"8-K","ticker":"PAVM","cik":"0001624326","company_name":"PAVmed Inc.","filed_at":"2025-01-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.224345+00:00","generated_at":"2026-05-27T11:14:03.564957+00:00","sec_items":["3.01","3.02","3.03","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PAVmed receives Nasdaq minimum bid price deficiency notice; sells Series C preferred shares","bullets":["Nasdaq notice on Jan 23: common stock closing bid below $1 for 30 consecutive days; 180-day cure period until July 22, 2025.","To regain compliance, closing bid must be at least $1 for 10 consecutive business days.","On Jan 24, sold 2,653 Series C Convertible Preferred shares for ~$2.653M via cancellation of unsecured debt.","Conversion at voluntary price $1.068/share would issue ~2.48M common shares; at floor $0.2136, ~12.42M shares.","Company intends to consider all available options to regain compliance with Nasdaq listing standards."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-003631","json":"https://secwatch.observer/filing/0001493152-25-003631.json","markdown":"https://secwatch.observer/filing/0001493152-25-003631.md","text":"https://secwatch.observer/filing/0001493152-25-003631.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1624326/000149315225003631/0001493152-25-003631-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1624326/000149315225003631/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T11:14:03.564957+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"01fa7671be6516dc25ef0ab30cc14bd838069216","claim":"PAVmed Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"January 23, 2025, PAVmed Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that, for the prior 30 consecutive business days (through J","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1624326/000149315225003631/0001493152-25-003631-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001493152-26-025244","ticker":"XHLD","company_name":"TEN Holdings, Inc.","filed_at":"2026-05-26T20:05:22+00:00","headline":"TEN Holdings receives Nasdaq equity deficiency notice; issues 500k shares for $500k","event_type":"regulatory","sec_items":["1.01","3.01","3.02","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 3.02, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025244","json":"https://secwatch.observer/filing/0001493152-26-025244.json","markdown":"https://secwatch.observer/filing/0001493152-26-025244.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2030954/000149315226025244/0001493152-26-025244-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2030954/000149315226025244/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 23, 2025, PAVmed Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The\nNasdaq Stock Market LLC (“ Nasdaq ”) stating that, for the prior 30 consecutive business days (through J","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1624326/000149315225003631/0001493152-25-003631-index.htm","comparable_excerpt":"May 26, 2026, the Company received a deficiency letter from the Listing Qualifications Department (the “ Staff ”)\nof The Nasdaq Stock Market LLC (“ Nasdaq ”), notifying the Company that it is not in compliance with Nasda","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2030954/000149315226025244/0001493152-26-025244-index.htm"}},{"accession":"0001731122-26-000668","ticker":"SBEV","company_name":"SPLASH BEVERAGE GROUP, INC.","filed_at":"2026-05-05T23:59:59+00:00","headline":"Splash Beverage receives NYSE delisting notice; shareholders' equity negative $15.3M","event_type":"regulatory","sec_items":["1.01","1.02","3.01","3.02","5.03","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 3.02, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-26-000668","json":"https://secwatch.observer/filing/0001731122-26-000668.json","markdown":"https://secwatch.observer/filing/0001731122-26-000668.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553788/000173112226000668/0001731122-26-000668-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553788/000173112226000668/e7604_8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 23, 2025, PAVmed Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The\nNasdaq Stock Market LLC (“ Nasdaq ”) stating that, for the prior 30 consecutive business days (through J","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1624326/000149315225003631/0001493152-25-003631-index.htm","comparable_excerpt":"April 29, 2026, the Company received notice from NYSE Regulation (the “NYSE”)\nthat the Company is not in compliance with the shareholders’ equity requirement of $6 million as of December 31, 2025 as outlined\nin Section 1","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1553788/000173112226000668/0001731122-26-000668-index.htm"}},{"accession":"0001213900-26-049432","ticker":"PFSA","company_name":"Profusa, Inc.","filed_at":"2026-04-29T23:59:59+00:00","headline":"Profusa faces Nasdaq delisting for MVPHS failure; amends debt and warrant terms","event_type":"regulatory","sec_items":["1.01","2.03","3.03","3.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 3.03, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-049432","json":"https://secwatch.observer/filing/0001213900-26-049432.json","markdown":"https://secwatch.observer/filing/0001213900-26-049432.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1859807/000121390026049432/0001213900-26-049432-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1859807/000121390026049432/ea0288135-8k_profusa.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 23, 2025, PAVmed Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The\nNasdaq Stock Market LLC (“ Nasdaq ”) stating that, for the prior 30 consecutive business days (through J","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1624326/000149315225003631/0001493152-25-003631-index.htm","comparable_excerpt":"April 28, 2026, the Company received written notification from the\nNasdaq Listing Qualifications Department (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”)\nthat the Company had not regained compliance with Na","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1859807/000121390026049432/0001213900-26-049432-index.htm"}},{"accession":"0001213900-26-063806","ticker":"ILLR","company_name":"Triller Group Inc.","filed_at":"2026-06-02T12:26:59+00:00","headline":"Triller gets Nasdaq bid-price exception until June 30, 2026","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063806","json":"https://secwatch.observer/filing/0001213900-26-063806.json","markdown":"https://secwatch.observer/filing/0001213900-26-063806.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1769624/000121390026063806/0001213900-26-063806-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1769624/000121390026063806/ea0292925-8k_triller.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 23, 2025, PAVmed Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The\nNasdaq Stock Market LLC (“ Nasdaq ”) stating that, for the prior 30 consecutive business days (through J","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1624326/000149315225003631/0001493152-25-003631-index.htm","comparable_excerpt":"May 29, 2026, the Nasdaq Hearings Panel (the\n“Panel”) notified Triller Group Inc. (“Triller” or the “Company”) that the Panel determined to grant\nTriller an exception to the Listing Rules of The Nasdaq Stock Market (“Nasdaq” or the “Exchange”) until June 30,\n2026 in order to regain compliance with Listing Rule 5550(a)(2) (the “Bid Price Rule”). As previously disclosed on April 24, 2026, following\na successful appeal by the Company to the Nasdaq Stock Market Listing and Hearing Review Council (the “Listing Council”) which\nmodified a previous December 26, 2025 decision by a Nasdaq Hearings Panel","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1769624/000121390026063806/0001213900-26-063806-index.htm"}},{"accession":"0001193125-26-251421","ticker":"GENC","company_name":"GENCOR INDUSTRIES INC","filed_at":"2026-06-01T20:09:26+00:00","headline":"Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251421","json":"https://secwatch.observer/filing/0001193125-26-251421.json","markdown":"https://secwatch.observer/filing/0001193125-26-251421.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/d135716d8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 23, 2025, PAVmed Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The\nNasdaq Stock Market LLC (“ Nasdaq ”) stating that, for the prior 30 consecutive business days (through J","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1624326/000149315225003631/0001493152-25-003631-index.htm","comparable_excerpt":"May 19, 2026, Gencor Industries, Inc. (the “Company”) received a notice (the “Delinquency Notification”) from NYSE Regulation (the “NYSE”) indicating the Company was not in compliance with the NYSE American LLC (“NYSE American”) continued listing standards as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”) prior to May 18, 2026, the end of the extension period provided by Form 12b-25, and as a result was subject to the procedures set forth in Section 1007 of the NY","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm"}},{"accession":"0001493152-26-026520","ticker":"NUTR","company_name":"NUSATRIP Inc","filed_at":"2026-06-01T11:10:27+00:00","headline":"NusaTrip receives Nasdaq delinquency notice for late 10-K and 10-Q; faces delisting if not compliant by Oct 12, 2026","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026520","json":"https://secwatch.observer/filing/0001493152-26-026520.json","markdown":"https://secwatch.observer/filing/0001493152-26-026520.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2006468/000149315226026520/0001493152-26-026520-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2006468/000149315226026520/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 23, 2025, PAVmed Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The\nNasdaq Stock Market LLC (“ Nasdaq ”) stating that, for the prior 30 consecutive business days (through J","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1624326/000149315225003631/0001493152-25-003631-index.htm","comparable_excerpt":"May 27, 2026, NusaTrip Incorporated (the “Company”) received a delinquency notification letter (the “Notice”)\nfrom the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) due to the Company’s\nnon-compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) as a result of the Company’s failure to timely\nfile its Annual Report on Form 10-K for the period ended December 31, 2025 and its Quarterly Report on Form 10-Q for the period ended\nMarch 31, 2026 (collectively, the “Delinquent Filings”). The Listing Rule requires listed companies to timely file all req","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2006468/000149315226026520/0001493152-26-026520-index.htm"}},{"accession":"0001213900-26-062935","ticker":"ATNM","company_name":"Actinium Pharmaceuticals, Inc.","filed_at":"2026-05-29T21:10:41+00:00","headline":"Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062935","json":"https://secwatch.observer/filing/0001213900-26-062935.json","markdown":"https://secwatch.observer/filing/0001213900-26-062935.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/ea0292691-8k_actinium.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 23, 2025, PAVmed Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The\nNasdaq Stock Market LLC (“ Nasdaq ”) stating that, for the prior 30 consecutive business days (through J","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1624326/000149315225003631/0001493152-25-003631-index.htm","comparable_excerpt":"May 27, 2026, Actinium Pharmaceuticals, Inc.\n(the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating\nthat the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company\nGuide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more\nif it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31,\n2026, the Company reported stockholders’ equity of approximately","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm"}},{"accession":"0001683168-26-004399","ticker":"CSAI","company_name":"CLOUDASTRUCTURE, INC.","filed_at":"2026-05-29T21:09:11+00:00","headline":"Cloudastructure receives Nasdaq delinquency notice for late Q1 10-Q filing","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-004399","json":"https://secwatch.observer/filing/0001683168-26-004399.json","markdown":"https://secwatch.observer/filing/0001683168-26-004399.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1709628/000168316826004399/0001683168-26-004399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1709628/000168316826004399/cloud_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 23, 2025, PAVmed Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The\nNasdaq Stock Market LLC (“ Nasdaq ”) stating that, for the prior 30 consecutive business days (through J","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1624326/000149315225003631/0001493152-25-003631-index.htm","comparable_excerpt":"May 26, 2026, Cloudastructure,\nInc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq\nStock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed its Quarterly Report on Form 10-Q for\nthe period ended March 31, 2026 (“Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which\nrequires timely filing of all required periodic financial reports with the Securities and Exchange Commission. The Company requires additional\ntime to review and confirm the accounting treatment for its outstand","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1709628/000168316826004399/0001683168-26-004399-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}